
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4560132/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nature Genetics, 2009, 41, 199-204.	21.4	1,229
2	An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	27.0	892
3	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	21.4	848
4	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, 43, 761-767.	21.4	778
5	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	13.7	722
6	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genetics, 2013, 45, 730-738.	21.4	699
7	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, The, 2013, 382, 780-789.	13.7	688
8	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine, 2015, 373, 1329-1339.	27.0	629
9	Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nature Genetics, 2010, 42, 991-995.	21.4	331
10	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet, The, 2017, 389, 2317-2327.	13.7	316
11	Genome-wide association analysis identifies three psoriasis susceptibility loci. Nature Genetics, 2010, 42, 1000-1004.	21.4	313
12	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. American Journal of Human Genetics, 2012, 90, 796-808.	6.2	306
13	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nature Communications, 2017, 8, 15382.	12.8	251
14	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. American Journal of Human Genetics, 2015, 97, 816-836.	6.2	245
15	Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nature Genetics, 2006, 38, 556-560.	21.4	227
16	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications, 2015, 6, 7146.	12.8	220
17	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1126-1136.	13.7	206
18	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212687.	0.9	193

#	Article	IF	CITATIONS
19	Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes. American Journal of Human Genetics, 2014, 95, 162-172.	6.2	182
20	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nature Genetics, 2015, 47, 1085-1090.	21.4	164
21	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nature Communications, 2015, 6, 7001.	12.8	156
22	Association of interleukinâ€23 receptor variants with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 58, 1020-1025.	6.7	152
23	TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis. Journal of Investigative Dermatology, 2012, 132, 593-600.	0.7	148
24	Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology, 2017, 56, 1993-2003.	1.9	121
25	Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis and Rheumatism, 2006, 54, 2321-2325.	6.7	114
26	Genome-Wide Meta-Analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL. Journal of Investigative Dermatology, 2012, 132, 1133-1140.	0.7	99
27	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nature Communications, 2018, 9, 4178.	12.8	95
28	Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. Arthritis and Rheumatism, 1999, 42, 818-823.	6.7	94
29	Classification of osteoarthritis phenotypes by metabolomics analysis. BMJ Open, 2014, 4, e006286.	1.9	90
30	The Newfoundland population: a unique resource for genetic investigation of complex diseases. Human Molecular Genetics, 2003, 12, R167-R172.	2.9	83
31	Genetics of psoriasis and psoriatic arthritis: update and future direction. Journal of Rheumatology, 2008, 35, 1449-53.	2.0	79
32	Excessive paternal transmission in psoriatic arthritis. Arthritis and Rheumatism, 1999, 42, 1228-1231.	6.7	78
33	Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis. Journal of Rheumatology, 2009, 36, 137-140.	2.0	72
34	Association of theIL1 gene cluster with susceptibility to ankylosing spondylitis: An analysis of three Canadian populations. Arthritis and Rheumatism, 2006, 54, 974-985.	6.7	69
35	Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis. Rheumatology, 2016, 55, 1566-1574.	1.9	68
36	IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Annals of the Rheumatic Diseases, 2011, 70, 1594-1598.	0.9	60

#	Article	IF	CITATIONS
37	TGF-Î ² signal transduction pathways and osteoarthritis. Rheumatology International, 2015, 35, 1283-1292.	3.0	60
38	Genetics of susceptibility and treatment response in psoriatic arthritis. Nature Reviews Rheumatology, 2011, 7, 718-732.	8.0	55
39	ls it safe to lift COVID-19 travel bans? The Newfoundland story. Computational Mechanics, 2020, 66, 1081-1092.	4.0	54
40	Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Human Immunology, 2013, 74, 1333-1338.	2.4	51
41	Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. Rheumatic Disease Clinics of North America, 2015, 41, 623-642.	1.9	50
42	Genetic variability of human angiotensin onverting enzyme 2 (hACE2) among various ethnic populations. Molecular Genetics & Genomic Medicine, 2020, 8, e1344.	1.2	50
43	Psoriatic arthritis from a mechanistic perspective. Nature Reviews Rheumatology, 2022, 18, 311-325.	8.0	49
44	Efficacy and Safety of Guselkumab, an Interleukinâ€23p19–Specific Monoclonal Antibody, Through One Year in Biologicâ€Naive Patients With Psoriatic Arthritis. Arthritis and Rheumatology, 2021, 73, 604-616.	5.6	48
45	Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. Journal of Rheumatology, 2010, 37, 1508-1512.	2.0	45
46	Relationship Between Blood Plasma and Synovial Fluid Metabolite Concentrations in Patients with Osteoarthritis. Journal of Rheumatology, 2015, 42, 859-865.	2.0	45
47	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. Journal of Rheumatology, 2018, 45, 378-384.	2.0	45
48	IL-23R Polymorphisms in Patients with Ankylosing Spondylitis in Korea: Table 1 Journal of Rheumatology, 2009, 36, 1003-1005.	2.0	42
49	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. Journal of Rheumatology, 2015, 42, 665-681.	2.0	42
50	Genome-wide DNA methylation study of hip and knee cartilage reveals embryonic organ and skeletal system morphogenesis as major pathways involved in osteoarthritis. BMC Musculoskeletal Disorders, 2015, 16, 287.	1.9	41
51	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 2017, 26, 4301-4313.	2.9	41
52	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology, 2020, 59, 1325-1334.	1.9	40
53	Genetics of psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2014, 28, 673-685.	3.3	39
54	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada. Journal of Rheumatology, 2015, 42, 654-664.	2.0	39

#	Article	IF	CITATIONS
55	Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis and Rheumatism, 2012, 64, 1119-1126.	6.7	38
56	pathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. Nucleic Acids Research, 2020, 48, D479-D488.	14.5	38
57	The Genetics of Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2019, 95, 46-50.	2.0	38
58	Overexpression of MMP13 in human osteoarthritic cartilage is associated with the SMAD-independent TGF-β signalling pathway. Arthritis Research and Therapy, 2015, 17, 264.	3.5	37
59	Metabolomic analysis of human synovial fluid and plasma reveals that phosphatidylcholine metabolism is associated with both osteoarthritis and diabetes mellitus. Metabolomics, 2016, 12, 1.	3.0	37
60	Metabolomics of osteoarthritis: emerging novel markers and their potential clinical utility. Rheumatology, 2018, 57, 2087-2095.	1.9	35
61	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time. Scientific Reports, 2019, 9, 9648.	3.3	34
62	Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences. Journal of rheumatology Supplement, The, 2010, 85, 11-26.	2.2	33
63	Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. Journal of Rheumatology, 2016, 43, 495-503.	2.0	32
64	Fine mapping of eight psoriasis susceptibility loci. European Journal of Human Genetics, 2015, 23, 844-853.	2.8	25
65	Update on the genetics of spondyloarthritis – ankylosing spondylitis and psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 579-588.	3.3	24
66	Pharmacogenetics of psoriasis. Pharmacogenomics, 2011, 12, 87-101.	1.3	24
67	Bone Morphogenetic Protein 6 Polymorphisms Are Associated with Radiographic Progression in Ankylosing Spondylitis. PLoS ONE, 2014, 9, e104966.	2.5	24
68	Metabolomics Signature for Nonâ€Responders to Total Joint Replacement Surgery in Primary Osteoarthritis Patients: The Newfoundland Osteoarthritis Study. Journal of Orthopaedic Research, 2020, 38, 793-802.	2.3	23
69	Complexities in Genetics of Psoriatic Arthritis. Current Rheumatology Reports, 2020, 22, 10.	4.7	23
70	Genetic structure of the Newfoundland and Labrador population: founder effects modulate variability. European Journal of Human Genetics, 2016, 24, 1063-1070.	2.8	22
71	Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. Rheumatology, 2021, 60, 2735-2744.	1.9	21
72	Integrated Genomics Identifies Convergence of Ankylosing Spondylitis with Global Immune Mediated Disease Pathways. Scientific Reports, 2015, 5, 10314.	3.3	20

#	Article	IF	CITATIONS
73	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). Scientific Reports, 2020, 10, 4925.	3.3	20
74	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1815-1823.	2.0	20
75	High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 690-694.	0.9	19
76	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology, 2021, 60, 5337-5350.	1.9	18
77	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Annals of the Rheumatic Diseases, 2021, 80, 1022-1030.	0.9	18
78	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open, 2021, 7, e001600.	3.8	18
79	A variant of the <i>IL4</i> I50V singleâ€nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. Arthritis and Rheumatism, 2008, 58, 2207-2208.	6.7	17
80	Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 923-935.	3.3	17
81	Private rare deletions in <i>SEC16A</i> and <i>MAMDC4</i> may represent novel pathogenic variants in familial axial spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 772-779.	0.9	17
82	SMAD3 Is Associated with the Total Burden of Radiographic Osteoarthritis: The Chingford Study. PLoS ONE, 2014, 9, e97786.	2.5	17
83	Metabolomic analysis coupled with extreme phenotype sampling identified that lysophosphatidylcholines are associated with multisite musculoskeletal pain. Pain, 2021, 162, 600-608.	4.2	17
84	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. Journal of Rheumatology, 2011, 38, 1343-1348.	2.0	16
85	Macrophage migration inhibitory factor may play a protective role in osteoarthritis. Arthritis Research and Therapy, 2021, 23, 59.	3.5	16
86	Further Evidence Supporting a Parentâ€ofâ€Origin Effect in Psoriatic Disease. Arthritis Care and Research, 2015, 67, 1586-1590.	3.4	15
87	A review of ustekinumab in the treatment of psoriatic arthritis. Immunotherapy, 2018, 10, 361-372.	2.0	15
88	Modelling the impact of travel restrictions on COVID-19 cases in Newfoundland and Labrador. Royal Society Open Science, 2021, 8, 202266.	2.4	15
89	Genome-Wide Signatures of â€ [~] Rearrangement Hotspots' within Segmental Duplications in Humans. PLoS ONE, 2011, 6, e28853.	2.5	14
90	Restricting Branched-Chain Amino Acids within a High-Fat Diet Prevents Obesity. Metabolites, 2022, 12, 334.	2.9	14

#	Article	IF	CITATIONS
91	Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics, 2008, 9, 195-205.	1.3	13
92	Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients. Arthritis Research and Therapy, 2019, 21, 224.	3.5	13
93	Single-cell transcriptome identifies FCGR3B upregulated subtype of alveolar macrophages in patients with critical COVID-19. IScience, 2021, 24, 103030.	4.1	13
94	Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open, 2016, 6, e009661.	1.9	12
95	A review of ixekizumab in the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 2018, 14, 993-1002.	3.0	12
96	Differential correlation network analysis identified novel metabolomics signatures for non-responders to total joint replacement in primary osteoarthritis patients. Metabolomics, 2020, 16, 61.	3.0	12
97	Advances in the Genetics of Spondyloarthritis and Clinical Implications. Current Rheumatology Reports, 2013, 15, 347.	4.7	11
98	Rat Bite Fever Resembling Rheumatoid Arthritis. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-7.	1.9	11
99	SMAD3 Is Upregulated in Human Osteoarthritic Cartilage Independent of the Promoter DNA Methylation. Journal of Rheumatology, 2016, 43, 388-394.	2.0	10
100	Ustekinumab in psoriatic arthritis and related phenotypes. Therapeutic Advances in Chronic Disease, 2018, 9, 191-198.	2.5	10
101	Phenylalanine Is a Novel Marker for Radiographic Knee Osteoarthritis Progression: The MOST Study. Journal of Rheumatology, 2021, 48, 123-128.	2.0	10
102	Association Between Epidemiological Factors and Nonresponders to Total Joint Replacement Surgery in Primary Osteoarthritis Patients. Journal of Arthroplasty, 2021, 36, 1502-1510.e5.	3.1	10
103	Identifying Aspects of Public Attitudes Toward Whole Genome Sequencing to Inform the Integration of Genomics into Care. Public Health Genomics, 2021, 24, 229-240.	1.0	10
104	Insights into the pathogenesis of psoriatic arthritis from genetic studies. Seminars in Immunopathology, 2021, 43, 221-234.	6.1	9
105	Where Do We Stand With the Genetics of Psoriatic Arthritis?. Current Rheumatology Reports, 2010, 12, 300-308.	4.7	8
106	Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. Rheumatology, 2019, 58, 522-526.	1.9	8
107	Public interest in whole genome sequencing and information needs: an online survey study. Personalized Medicine, 2020, 17, 283-293.	1.5	8
108	Genetics of ankylosing spondylitis: An update. Current Rheumatology Reports, 2007, 9, 383-389.	4.7	7

#	Article	IF	CITATIONS
109	Mutational Landscape of Autism Spectrum Disorder Brain Tissue. Genes, 2022, 13, 207.	2.4	7
110	Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC. Frontiers in Genetics, 2019, 10, 304.	2.3	6
111	Expression and Metabolomic Profiling in Axial Spondyloarthritis. Current Rheumatology Reports, 2018, 20, 51.	4.7	5
112	Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. Scientific Reports, 2020, 10, 21703.	3.3	5
113	Clinical and molecular significance of genetic loci associated with psoriatic arthritis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101691.	3.3	5
114	Genetics of psoriatic arthritis. , 2018, , .		5
115	High Accuracy and Significant Savings Using Tag-SNP Genotyping to Determine <i>HLA-B*27</i> Status. Journal of Rheumatology, 2017, 44, 962.2-963.	2.0	5
116	Privacy protection and public goods: building a genetic database for health research in Newfoundland and Labrador. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 38-43.	4.4	4
117	Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine. Expert Review of Precision Medicine and Drug Development, 2020, 5, 35-42.	0.7	4
118	Sphingomyelin is involved in multisite musculoskeletal pain: evidence from metabolomic analysis in 2 independent cohorts. Pain, 2021, 162, 1876-1881.	4.2	4
119	256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. Rheumatology, 2019, 58, .	1.9	3
120	Genetic Epidemiology of Complex Phenotypes. Methods in Molecular Biology, 2021, 2249, 335-367.	0.9	3
121	Spinal mobility in radiographic axial spondyloarthritis: criterion concurrent validity of classic and novel measurements. BMC Musculoskeletal Disorders, 2021, 22, 464.	1.9	3
122	Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort. Rheumatology, 2022, 61, 4952-4961.	1.9	3
123	Metabolomic signatures for the longitudinal reduction of muscle strength over 10 years. Skeletal Muscle, 2022, 12, 4.	4.2	3
124	Current Challenges in the Genetics of Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. Journal of Rheumatology, 2011, 38, 564-566.	2.0	2
125	Real-world Experience of Using <i>HLA-B*27</i> Tag-single-nucleotide Polymorphism Assay to Screen for Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1712-1712.	2.0	2
126	Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry. BMJ Open, 2020, 10, e036245.	1.9	2

#	Article	IF	CITATIONS
127	Probing for genes in seronegative spondyloarthropathy. Current Rheumatology Reports, 2000, 2, 306-310.	4.7	1
128	Powered for Success: Considerations for Using the Candidate Gene Approach in Rheumatic Diseases in the Post-genomics Era. Journal of Rheumatology, 2014, 41, 1573-1575.	2.0	1
129	Public interest in unexpected genomic findings: a survey study identifying aspects of sequencing attitudes that influence preferences. Journal of Community Genetics, 2022, 13, 235-245.	1.2	1
130	Variability of haplotype phase and its effect on genetic analysis. Canadian Conference on Electrical and Computer Engineering, 2008, , .	0.0	0
131	P250 Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. Rheumatology, 2020, 59, .	1.9	0
132	P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. Rheumatology, 2020, 59, .	1.9	0